RobertJGrayMD

Family Medicine • Miramar, FL

Physician

Join to view full profile

Are you Dr. Gray?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 40 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
3601 Sw 160th Ave
Ste 250
Miramar, FL 33027
Phone+1 877-866-7123
Is this information wrong?

Summary

Dr. Robert Gray, MD is a family physician in Miramar, Florida. He is currently licensed to practice medicine in Pennsylvania.

Education & Training

UPMC Medical Education/Williamsport HospitalResidency, Family Medicine, 1992 - 1995
Pennsylvania State University College of MedicineClass of 1992

Certifications & Licensure

PA State Medical License 1994 - 2020

Publications & Presentations

PubMed

TAILORx: Questions Answered, Lessons Learned, and Remaining Knowledge Gaps.
Sparano, J. A.,Gray, R.> ;J. Clin. Oncol.. 2019 Jun 08
Pragmatic approaches to address expansion cohort design.
Dahlberg, S. E.,Gray, R. J.> ;Cancer. 2018 Jul 06
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Sparano, J. A.,Gray, R. J.,Makower, D. F.,Pritchard, K. I.,Albain, K. S.,Hayes, D. F.,Geyer, C. E.,Dees, E. C.,Goetz, M. P.,Olson, J. A.,Lively, T.,Badve, S. S.,Saphne...> ;N. Engl. J. Med.. 2018 Jun 05
E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer.
Yeruva, SLH.,Zhao, F.,Miller, K. D.,Tevaarwerk, A. J.,Wagner, L. I.,Gray, R. J.,Sparano, J. A.,Connolly, R. M.> ;NPJ Breast Cancer. 2018 Jan 23
Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort s...
Rakovitch, E.,Gray, R.,Baehner, F. L.,Sutradhar, R.,Crager, M.,Gu, S.,Nofech-Mozes, S.,Badve, S. S.,Hanna, W.,Hughes, L. L.,Wood, W. C.,Davidson, N. E.,Paszat, L.,Shak...> ;Breast Cancer Res. Treat.. 2018 Feb 02
A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer.
Sparano, J. A.,Gray, R.,Oktay, M. H.,Entenberg, D.,Rohan, T.,Xue, X.,Donovan, M.,Peterson, M.,Shuber, A.,Hamilton, D. A.,D'Alfonso, T.,Goldstein, L. J.,Gertler, F.,Dav...> ;NPJ Breast Cancer. 2017 Nov 16
Estimating treatment effect in a proportional hazards model in randomized clinical trials with all-or-nothing compliance.
Li S, Gray RJ> ;Biometrics. 2016-09-01
Reply to C. Shah et al.
Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, Baehner FL, Ingle JN, Perez EA, Recht A, Sparano JA, Davidson NE> ;J. Clin. Oncol.. 2016-05-20
937 citations
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
Joseph A. Sparano, Robert Gray, D. F. Makower, Kathleen I. Pritchard, Kathy S. Albain, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, E. A. Perez, John A. O...> ;The New England Journal of Medicine. 2015 Nov 18
Reply to S. Goteti et al.
Freidlin B, Sun Z, Gray R, Korn EL> ;J. Clin. Oncol.. 2014-03-10
Marker Sequential Test (MaST) design.
Freidlin, B.,Korn, E. L.,Gray, R.> ;Clin Trials. 2013 Oct 1
Phase III clinical trials that integrate treatment and biomarker evaluation.
Freidlin B, Sun Z, Gray R, Korn EL> ;J. Clin. Oncol.. 2013-09-01
An audit strategy for time-to-event outcomes measured with error: Application to five randomized controlled trials in oncology.
Dodd, L. E.,Korn, E. L.,Freidlin, B.,Gu, W.,Abrams, J. S.,Bushnell, W. D.,Canetta, R.,Doroshow, J. H.,Gray, R. J.,Sridhara, R.> ;Clin Trials. 2013
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.
Solin, L. J.,Gray, R.,Baehner, F. L.,Butler, S. M.,Hughes, L. L.,Yoshizawa, C.,Cherbavaz, D. B.,Shak, S.,Page, D. L.,Sledge, G. W.,Davidson, N. E.,Ingle, J. N.,Perez, ...> ;J. Natl. Cancer Inst.. 2013 May 15
Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: Little evidence of improvement over the past 30 years.
Tevaarwerk, A. J.,Gray, R. J.,Schneider, B. P.,Smith, M. L.,Wagner, L. I.,Fetting, J. H.,Davidson, N.,Goldstein, L. J.,Miller, K. D.,Sparano, J. A.> ;Cancer. 2013 Mar 15
Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bev...
Schneider, B. P.,Gray, R. J.,Radovich, M.,Shen, F.,Vance, G.,Li, L.,Jiang, G.,Miller, K. D.,Gralow, J. R.,Dickler, M. N.,Cobleigh, M. A.,Perez, E. A.,Shenkier, T. N.,V...> ;Clin Cancer Res. 2013 Mar 1
Three-component cure rate model for nonproportional hazards alternative in the design of randomized clinical trials.
Kim HT, Gray R> ;Clin Trials. 2012-04-01
35 citations
Nerve sparing can preserve orgasmic function in most men after robotic-assisted laparoscopic radical prostatectomy.
Ashutosh Tewari, Sonal Grover, Prasanna Sooriakumaran, Abhishek Kumar Srivastava, Sandhya Rao, Amit Gupta, Robert Gray, Robert Leung, Darius A. Paduch> ;BJU International. 2012 Feb 1
54 citations
Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups.
Anneke T. Schroen, Gina R. Petroni, Hongkun Wang, Monika J. Thielen, Robert Gray, Jacqueline Benedetti, Xiaofei Wang, Daniel J. Sargent, D L Wickerham, Walter M. Croni...> ;Clinical Cancer Research. 2012 Jan 1
16 citations
Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials
Anneke T. Schroen, Gina R. Petroni, Hongkun Wang, Monika J. Thielen, Daniel J. Sargent, Jacqueline Benedetti, Walter M. Cronin, D L Wickerham, Xiaofei Wang, Robert Gra...> ;Clinical Trials. 2011 Aug 30
When Bad Things Happen to Good Studies.
Manola, J.B., Gray, R.J.> ;J Clin Oncol. 2011 Sep 10
Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combina...
Brahmer, J.R., Dahlberg, S.E., Gray, R.J., Schiller, J.H., Perry, M.C., Sandler, A., Johnson, D.H.> ;J Thorac Oncol. 2011 Jan
74 citations
Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials
Anneke T. Schroen, Gina R. Petroni, Hongkun Wang, Robert Gray, Xiaofei Wang, Walter M. Cronin, Daniel J. Sargent, Jacqueline Benedetti, D L Wickerham, Benjamin Djulbeg...> ;Clinical Trials. 2010 Jul 1
Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer.
Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez E, Shulman LN, Martino S, Davidson NE, Sledge GW, Gray R> ;Clin. Cancer Res.. 2009-12-15
Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials.
Bhattacharya, S., Fyfe, G., Gray, R.J., Sargent, D.J.> ;J Clin Oncol. 2009-12-10
Join now to see all

Grant Support

ECOG Statistical Office Data Management GrantNational Cancer Institute2004–2011
ECOG Statistical OfficeNational Cancer Institute2000–2011
ECOG Statistical Center--Data Management OfficeNational Cancer Institute2000–2003
Modeling Failure Time Data In Cancer ResearchNational Cancer Institute1992–2002